Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder tumor (TURBT) was performed before NAC to define the pathology, impacting the real evaluation of NAC. This research aimed to assess real NAC efficacy without interference from TURBT and apply combined modality therapies guided by NAC efficacy. Materials and Methods Patients with cT2-4aN0M0 MIBC were confirmed by cystoscopic biopsy and imaging. NAC efficacy was assessed by imaging, urine cytology, and cystoscopy with multidisciplinary team discussion. Definite responders (≤ T1) underwent TURBT plus concurrent chemoradiotherapy. Incomplete responders underwent radical cystectomy or partial cystectomy if feasible. The primary endpoint was the bladder preservation rate. Results Fifty-nine patients were enrolled, and the median age was 63 years. Patients with cT3-4 accounted for 75%. The median number of NAC cycles was three. Definite responders were 52.5%. The complete response (CR) was 10.2%, and 59.3% of patients received bladder-sparing treatments. With a median follow-up of 44.6 months, the 3-year overall survival (OS) was 72.8%. Three-year OS and relapse-free survival were 88.4% and 60.0% in the bladder-sparing group but only 74.3% and 37.5% in the cystectomy group. The evaluations of preserved bladder function were satisfactory. Conclusion After stratifying MIBC patients by NAC efficacy, definite responders achieved a satisfactory bladder-sparing rate, prognosis, and bladder function. The CR rate reflected the real NAC efficacy for MIBC. This therapy is worth verifying through multicenter research.
Abstract
Purpose Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder tumor (TURBT) was performed before NAC to define the pathology, impacting the real evaluation of NAC. This research aimed to assess real NAC efficacy without interference from TURBT and apply combined modality therapies guided by NAC efficacy. Materials and Methods Patients with cT2-4aN0M0 MIBC were confirmed by cystoscopic biopsy and imaging. NAC efficacy was assessed by imaging, urine cytology, and cystoscopy with multidisciplinary team discussion. Definite responders (≤ T1) underwent TURBT plus concurrent chemoradiotherapy. Incomplete responders underwent radical cystectomy or partial cystectomy if feasible. The primary endpoint was the bladder preservation rate. Results Fifty-nine patients were enrolled, and the median age was 63 years. Patients with cT3-4 accounted for 75%. The median number of NAC cycles was three. Definite responders were 52.5%. The complete response (CR) was 10.2%, and 59.3% of patients received bladder-sparing treatments. With a median follow-up of 44.6 months, the 3-year overall survival (OS) was 72.8%. Three-year OS and relapse-free survival were 88.4% and 60.0% in the bladder-sparing group but only 74.3% and 37.5% in the cystectomy group. The evaluations of preserved bladder function were satisfactory. Conclusion After stratifying MIBC patients by NAC efficacy, definite responders achieved a satisfactory bladder-sparing rate, prognosis, and bladder function. The CR rate reflected the real NAC efficacy for MIBC. This therapy is worth verifying through multicenter research.
참고문헌 (30)
- Antoni S, "Bladder cancer incidence and mortality : a global overview and recent trends", Eur Urol, 71, pp.96~108 (2017)
- Flaig TW, "NCCN guidelines updates : management of muscleinvasive bladder cancer", J Natl Compr Canc Netw, 17, pp.591~593 (2019)
- International Collaboration of Trialists, "International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer : long-term results of the BA06 30894trial", J Clin Oncol, 29, pp.2171~2177 (2011)
- Parekh DJ, "Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer(RAZOR) : an open-label, randomised, phase 3, non-inferiority trial", Lancet, 391, pp.2525~2536 (2018)
- Yu HY, "Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy : results from the US Nationwide Inpatient Sample", Eur Urol, 61, pp.1239~1244 (2012)
- Winters BR, "Health related quality of life following radical cystectomy : comparative analysis from the medicare health outcomes survey", J Urol, 199, pp.669~675 (2018)
- Kulkarni GS, "Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic", J Clin Oncol, 35, pp.2299~2305 (2017)
- Efstathiou JA, "Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer : the MGH experience", Eur Urol, 61, pp.705~711 (2012)
- Giacalone NJ, "Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscleinvasive bladder cancer : an updated analysis of the Massachusetts General Hospital experience", Eur Urol, 71, pp.952~960 (2017)
- Grossman HB, "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer", N Engl J Med, 349, pp.859~866 (2003)
- Yeshchina O, "Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder", Urology, 79, pp.384~390 (2012)
- Galsky MD, "Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer", Cancer, 121, pp.2586~2593 (2015)
- Lee FC, "Pathologic response rates of gemcitabine", cisplatin versus methotrexate, adriamycin, pp.cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer, Adv Urol[DOI]
- Peyton CC, "Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer", JAMA Oncol, 4, pp.1535~1542 (2018)
- Stenzl A, "The updated EAU guidelines on muscle-invasive and metastatic bladder cancer", Eur Urol, 55, pp.815~825 (2009)
- van der Pol CB, "Update on multiparametric MRI of urinary bladder cancer", J Magn Reson Imaging, 48, pp.882~896 (2018)
- Takeuchi M, "Urinary bladder cancer : diffusion-weighted MR imaging : accuracy for diagnosing T stage and estimating histologic grade", Radiology, 251, pp.112~121 (2009)
- Donaldson SB, "Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect", Eur J Radiol, 82, pp.2161~2168 (2013)
- Shipley WU, "Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy : initial results of Radiation Therapy Oncology Group 89-03", J Clin Oncol, 16, pp.3576~3583 (1998)
- Mathieu R, "Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?", Curr Opin Urol, 25, pp.476~482 (2015)
- Ploussard G, "Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer : a systematic review", Eur Urol, 66, pp.120~137 (2014)
- Zapatero A, "Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer : neoadjuvant chemotherapy and concurrent radio-chemotherapy", Urology, 80, pp.1056~1062 (2012)
- Hautmann RE, "Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy : long-term results in 1100 patients", Eur Urol, 61, pp.1039~1047 (2012)
- Massari F, "Adjuvant and neoadjuvant approaches for urothelial cancer : updated indications and controversies", Cancer Treat Rev, 68, pp.80~85 (2018)
- Panebianco V, "Improving staging in bladder cancer : the increasing role of multiparametric magnetic resonance imaging", Eur Urol Focus, 2, pp.113~121 (2016)
- Panebianco V, "Multiparametric magnetic resonance imaging for bladder cancer : development of VI-RADS(Vesical Imaging-Reporting And Data System)", Eur Urol, 74, pp.294~306 (2018)
- Zhang M, "Utility of intravoxel incoherent motion MRI derived parameters for prediction of aggressiveness in urothelial bladder carcinoma", J Magn Reson Imaging, 48, pp.1648~1656 (2018)
- Inoue M, "Clinical outcome of chemoradiotherapy for T1G3 bladder cancer", Int J Urol, 15, pp.747~750 (2008)
- Meleis L, "Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer", J Oncol Pharm Pract, 26, pp.330~337 (2020)
- Huddart RA, "Clinical and patient-reported outcomes of SPARE : a randomised feasibility study of selective bladder preservation versus radical cystectomy", BJU Int, 120, pp.639~650 (2017)